» Articles » PMID: 27220013

Pharmacokinetics of Prolonged-release Tacrolimus and Implications for Use in Solid Organ Transplant Recipients

Overview
Journal Clin Transplant
Specialty General Surgery
Date 2016 May 25
PMID 27220013
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Prolonged-release tacrolimus was developed as a once-daily formulation with ethylcellulose as the excipient, resulting in slower release and reduction in peak concentration (Cmax ) for a given dose compared with immediate-release tacrolimus, which is administered twice daily. This manuscript reviews pharmacokinetic information on prolonged-release tacrolimus in healthy subjects, in transplant recipients converted from immediate-release tacrolimus, and in de novo kidney and liver transplant recipients. As with the immediate-release formulation, prolonged-release tacrolimus shows a strong correlation between trough concentration (Cmin ) and area under the 24-hour time-concentration curve (AUC24 ), indicating that trough whole blood concentrations provide an accurate measure of drug exposure. We present the pharmacokinetic similarities and differences between the two formulations, so that prescribing physicians will have a better understanding of therapeutic drug monitoring in patients receiving prolonged-release tacrolimus.

Citing Articles

The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report.

Fuessl L, Kreuzer L, Nierychlewski K, Seibt T, Stangl M, Koliogiannis D Front Med (Lausanne). 2024; 11:1336035.

PMID: 38988355 PMC: 11233442. DOI: 10.3389/fmed.2024.1336035.


Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis.

Gwinner W, Anaokar S, Blogg M, Hermann B, Repetur C, Schiffer M Ann Transplant. 2024; 29:e942167.

PMID: 38500255 PMC: 10960500. DOI: 10.12659/AOT.942167.


Evaluation of limited-sampling strategies to calculate AUC and the role of in Chilean pediatric kidney recipients using extended-release tacrolimus.

Galvez C, Boza P, Gonzalez M, Hormazabal C, Encina M, Azocar M Front Pharmacol. 2023; 14:1044050.

PMID: 36998611 PMC: 10043346. DOI: 10.3389/fphar.2023.1044050.


Outcomes in kidney transplant recipients treated with immediate-release tacrolimus capsules versus extended-release tacrolimus capsules: A cohort study.

Ha Y, Divard G, Mitra N, Putt M, Pallet N, Loupy A Clin Transplant. 2022; 37(1):e14840.

PMID: 36374204 PMC: 10290232. DOI: 10.1111/ctr.14840.


Immunosuppression as a Risk Factor for De Novo Angiotensin II Type Receptor Antibodies Development after Kidney Transplantation.

Sorohan B, Sinescu I, Tacu D, Bucsa C, Tincu C, Obrisca B J Clin Med. 2021; 10(22).

PMID: 34830672 PMC: 8625545. DOI: 10.3390/jcm10225390.